Proteomics International (ASX: PIQ) is a precision diagnostics company focused on the development and commercial launch of first-in-class blood-based diagnostic tests targeting diseases that are often detected late and are costly to manage. The Company operates a platform-based model, combining proprietary biomarkers, validated clinical data, accredited laboratories, and a digital sales pathway to support direct sales and future licensing across multiple tests and jurisdictio

Proteomics International (ASX: PIQ) has expanded its research agreement with the University of Melbourne and the Royal Women’s Hospital (RWH), a leading centre for endometriosis research. The partnership has two clear streams: (1) additional clinical validation for Promarker®Endo—PIQ’s first-in-class blood test for diagnosing endometriosis—and (2) discovery work toward a tissue-specific, next-generation test using peritoneal fluid to improve disease localisation.